Prognostic value of HER-2/neu expression in epithelial ovarian cancer: A meta-analysis

Tumor Biology

Volumn 35, Issue 1, 2014, Pages 33-38

  Wang, Yan ^a   Wang, Dong ^b   Ren, Mulan ^a  

^a SOUTHEAST UNIVERSITY   (China)

^b MEDICAL SCHOOL OF SOUTHEAST UNIVERSITY   (China)

Author keywords

HER 2 neu; Meta analysis; Ovarian cancer; Overall survival; Prognosis

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CONFIDENCE INTERVAL; FLUORESCENCE IN SITU HYBRIDIZATION; HAZARD RATIO; HUMAN; IMMUNOASSAY; META ANALYSIS (TOPIC); OVARY CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SOUTHERN BLOTTING; STUDY DESIGN; SURVIVAL RATE;

FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASMS, GLANDULAR AND EPITHELIAL; ODDS RATIO; OVARIAN NEOPLASMS; PATIENT OUTCOME ASSESSMENT; PROGNOSIS; PROSPECTIVE STUDIES; PUBLICATION BIAS; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES;

EID: 84893757821     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-1003-9     Document Type: Article

References (39)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277300.
2. Cannistra SA. Cancer of the ovary. N Engl JMed. 2004;351:251929.
3. Winter III WE, Maxwell GL, Tian C, Carlson JW, Ozols RF, Rose PG, et al. Prognostic factors for III stage epithelial ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2007;25:36217.
4. Oldenhuis CN, Oosting SF, Gietema JA, De Vries EG. Prognostic vs predictive value of biomarkers in oncology. Eur J Cancer. 2008;44:94653.
5. Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol. 2008;19:15239.
6. Altman DG. Systematic reviews of evaluations of prognostic variables. BMJ. 2001;323(7306):2248.
7. Zhan P, Qian Q, Yu LK. Prognostic value of COX-2 expression in patients with non-small cell lung cancer: a systematic review and meta-analysis. J Thorac Dis. 2013;5(1):407. doi:10.3978/j.issn. 2072-1439.2013.01.02.
8. Zhan P, Qian Q, Wan B, Yan TD, Yu LK. Prognostic value of TTF-1 expression in patients with non-small cell lung cancer: a meta-analysis. Transl Cancer Res. 2013. doi:10.3978/j.issn.2218-676X.2013.02.08.
9. Zhan P,Wang Q, Qian Q,Yu LK.Megestrol acetate in cancer patients with anorexia-cachexia syndrome: a meta-analysis. Transl Cancer Res. 2013;2(2):749. doi:10.3978/j.issn.2218-676X.2013.04.13.
10. Zhan P, Wang Q, Qian Q, Yu LK. Risk of venous thromboembolism with the erythropoiesis-stimulating agents (ESAs) for the treatment of cancer-associated anemia: ameta-analysis of randomized control trials. Chin Clin Oncol. 2013. doi:10.3978/j.issn.2304-3865.2013.01.02.
11. Zhan P, Qian Q, Yu LK. Prognostic significance of Vascular endothelial growth factor expression in hepatocellular carcinoma tissue: a meta-analysis. Hepatobiliary Surg Nutr. 2013. doi:10.3978/j.issn. 2304-3881.2013.06.06.
12. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17:281534.
13. Yusuf S, Peto R, Lewis J, et al. Blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis. 1985;27:33571.
14. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:17788.
15. Egger M, Smith GD, Schneider M. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:62934.
16. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088101.
17. Berchuck A, Kamel A, Whitaker R, Kerns B, Olt G, Kinney R, et al. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res. 1990;50:408791.
18. Fajac A, Benard J, Lhomme C, Rey A, Duvillard P, Rochard F, et al. c-erbB2 gene amplification and protein expression in ovarian epithelial tumors: evaluation of their respective prognostic significance by multivariate analysis. Int J Cancer. 1995;64:14651.
19. Kaufmann M, Von Minckwitz G, Kuhn W, Schmid H, Costa S, Goerttler K, et al. Combination of new biologic parameters as a prognostic index in epithelial ovarian carcinoma. Int J Gynecol Cancer. 1995;5:4955.
20. Medl M, Sevelda P, Czerwenka K, Dobianer K, Hanak H, Hruza C, et al. DNA amplification of HER-2/neu and INT-2 oncogenes in epithelial ovarian cancer. Gynecol Oncol. 1995;59:3216.
21. Wang ZR, Liu W, Smith ST, Parrish RS, Young SR. c-myc and chromosome 8 centromere studies of ovarian cancer by interphase FISH. Exp Mol Pathol. 1999;66:1408.
22. Davidson B, Gotlieb WH, Ben Baruch G, Nesland JM, Bryne M, Goldberg I, et al. E-cadherin complex protein expression and survival in ovarian carcinoma. Gynecol Oncol. 2000;79:36271.
23. Skirnisdottir I, Sorbe B, Seidal T. The growth factor receptors HER- 2/neu and EGFR, their relationship, and their effects on the prognosis in early stage (FIGO I-II) epithelial ovarian carcinoma. Int J Gynecol Cancer. 2001;11:11929.
24. Camilleri-Broet S, Hardy-Bessard AC, Le Tourneau A, Paraiso D, Levrel O, Leduc B, et al. HER-2 overexpression is an independent marker of poor prognosis of advanced primary ovarian carcinoma: a multicenter study of theGINECO group.Ann Oncol. 2004;15:10412.
25. Nielsen JS, Jakobsen E, Holund B, Bertelsen K, Jakobsen A. Prognostic significance of p53, Her-2, and EGFR overexpression in borderline and epithelial ovarian cancer. Int J Gynecol Cancer. 2004;14:108696.
26. Verri E, Guglielmini P, Puntoni M, Perdelli L, Papadia A, Lorenzi P, et al. HER2/neu oncoprotein overexpression in epithelial ovarian cancer: evaluation of its prevalence and prognostic significance. Clinical study Oncology. 2005;68:15461.
27. Wang Y, Kristensen GB, Helland A, Nesland JM, Borresen-Dale AL, Holm R. Protein expression and prognostic value of genes in the erb-b signaling pathway in advanced ovarian carcinomas. Am J Clin Pathol. 2005;124:392401.
28. Castellvi J, Garcia A, Rojo F, Ruiz-Marcellan C, Gil A, Baselga J, et al. Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancer. Cancer. 2006;107:180111.
29. Surowiak P, Materna V, Kaplenko I, Spaczynski M, Dietel M, Lage H, et al. Topoisomerase 1A, HER/2neu and Ki67 expression in paired primary and relapse ovarian cancer tissue samples. Histol Histopathol. 2006;21:71320.
30. Malamou-Mitsi V, Crikoni O, Timotheadou E, Aravantinos G, Vrettou E, Agnantis N, et al. Prognostic significance of HER-2, p53 and Bcl-2 in patients with epithelial ovarian cancer. Anticancer Res. 2007;27:115765.
31. Pils D, Pinter A, Reibenwein J, Alfanz A, Horak P, Schmid BC, et al. In ovarian cancer the prognostic influence ofHER2/neu is not dependent on the CXCR4/SDF-1 signalling pathway. Br J Cancer. 2007;96:48591.
32. Steffensen KD,Waldstrom M, Jeppesen U, Jakobsen E, Brandslund I, Jakobsen A. The prognostic importance of cyclooxygenase 2 and HER2 expression in epithelial ovarian cancer. International Journal of Gynecological Cancer. 2007;17:798807.
33. TuefferdM, Couturier J, Penault-Llorca F, Vincent-Salomon A, Broet P, Guastalla JP, et al. HER2 status in ovarian carcinomas: a multicenter GINECO study of 320 patients. PLoS One. 2007;2(11):e1138.
34. de Graeff P, Crijns AP, Ten Hoor KA, Klip HG, Hollema H, Oien K, et al. The ErbB signalling pathway: protein expression and prognostic value in epithelial ovarian cancer. Br J Cancer. 2008;99:3419.
35. Garcia-Velasco A, Mendiola C, Sanchez-Munoz A, Ballestin C, Colomer R, Cortes-Funes H. Prognostic value of hormonal receptors, p53, ki67 and HER2/neu expression in epithelial ovarian carcinoma. Clin Transl Oncol. 2008;10:36771.
36. Tomsova M, Melichar B, Sedlakova I, Steiner I. Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma. Gynecol Oncol. 2008;108:41520.
37. Shih C, Padhy L, Murray M, Weinberg RA. Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts. Nature. 1981;260:2614.
38. Slamon DJ, GodolphinW, Jones LA, Holt JA,Wong SG, Keith DE, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244:70712.
39. Begg CB, Berlin JA. Publication bias: a problem in interpreting medical data. J R Stat Soc A. 1988;151:41963.